Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Equivalence of Enoxaparin Rovi vs Clexane in Healthy Volunteers
NCT03363477Phase 1Completed
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoints: Area Under the Effect Curve from time zero to infinity for anti-FXa activity, Area Under the Effect Curve from time zero to the last measurable concentration for anti-FXa and anti-FIIa and 1 more. Started Sep 2015; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03363477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363477.